141 related articles for article (PubMed ID: 26351136)
1. Screening of HELQ in breast and ovarian cancer families.
Pelttari LM; Kinnunen L; Kiiski JI; Khan S; Blomqvist C; Aittomäki K; Nevanlinna H
Fam Cancer; 2016 Jan; 15(1):19-23. PubMed ID: 26351136
[TBL] [Abstract][Full Text] [Related]
2. RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families.
Pelttari LM; Kiiski JI; Ranta S; Vilske S; Blomqvist C; Aittomäki K; Nevanlinna H
Springerplus; 2015; 4():92. PubMed ID: 25918678
[TBL] [Abstract][Full Text] [Related]
3. Germline mutation in the RAD51B gene confers predisposition to breast cancer.
Golmard L; Caux-Moncoutier V; Davy G; Al Ageeli E; Poirot B; Tirapo C; Michaux D; Barbaroux C; d'Enghien CD; Nicolas A; Castéra L; Sastre-Garau X; Stern MH; Houdayer C; Stoppa-Lyonnet D
BMC Cancer; 2013 Oct; 13():484. PubMed ID: 24139550
[TBL] [Abstract][Full Text] [Related]
4. A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer.
Pelttari LM; Kiiski J; Nurminen R; Kallioniemi A; Schleutker J; Gylfe A; Aaltonen LA; Leminen A; Heikkilä P; Blomqvist C; Bützow R; Aittomäki K; Nevanlinna H
J Med Genet; 2012 Jul; 49(7):429-32. PubMed ID: 22652533
[TBL] [Abstract][Full Text] [Related]
5. RAD51B in Familial Breast Cancer.
Pelttari LM; Khan S; Vuorela M; Kiiski JI; Vilske S; Nevanlinna V; Ranta S; Schleutker J; Winqvist R; Kallioniemi A; Dörk T; Bogdanova NV; Figueroa J; Pharoah PD; Schmidt MK; Dunning AM; García-Closas M; Bolla MK; Dennis J; Michailidou K; Wang Q; Hopper JL; Southey MC; Rosenberg EH; Fasching PA; Beckmann MW; Peto J; Dos-Santos-Silva I; Sawyer EJ; Tomlinson I; Burwinkel B; Surowy H; Guénel P; Truong T; Bojesen SE; Nordestgaard BG; Benitez J; González-Neira A; Neuhausen SL; Anton-Culver H; Brenner H; Arndt V; Meindl A; Schmutzler RK; Brauch H; Brüning T; Lindblom A; Margolin S; Mannermaa A; Hartikainen JM; Chenevix-Trench G; ; Van Dyck L; Janssen H; Chang-Claude J; Rudolph A; Radice P; Peterlongo P; Hallberg E; Olson JE; Giles GG; Milne RL; Haiman CA; Schumacher F; Simard J; Dumont M; Kristensen V; Borresen-Dale AL; Zheng W; Beeghly-Fadiel A; Grip M; Andrulis IL; Glendon G; Devilee P; Seynaeve C; Hooning MJ; Collée M; Cox A; Cross SS; Shah M; Luben RN; Hamann U; Torres D; Jakubowska A; Lubinski J; Couch FJ; Yannoukakos D; Orr N; Swerdlow A; Darabi H; Li J; Czene K; Hall P; Easton DF; Mattson J; Blomqvist C; Aittomäki K; Nevanlinna H
PLoS One; 2016; 11(5):e0153788. PubMed ID: 27149063
[TBL] [Abstract][Full Text] [Related]
6. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.
Vuorela M; Pylkäs K; Hartikainen JM; Sundfeldt K; Lindblom A; von Wachenfeldt Wäppling A; Haanpää M; Puistola U; Rosengren A; Anttila M; Kosma VM; Mannermaa A; Winqvist R
Breast Cancer Res Treat; 2011 Dec; 130(3):1003-10. PubMed ID: 21750962
[TBL] [Abstract][Full Text] [Related]
7. Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.
Golmard L; Castéra L; Krieger S; Moncoutier V; Abidallah K; Tenreiro H; Laugé A; Tarabeux J; Millot GA; Nicolas A; Laé M; Abadie C; Berthet P; Polycarpe F; Frébourg T; Elan C; de Pauw A; Gauthier-Villars M; Buecher B; Stern MH; Stoppa-Lyonnet D; Vaur D; Houdayer C
Eur J Hum Genet; 2017 Dec; 25(12):1345-1353. PubMed ID: 29255180
[TBL] [Abstract][Full Text] [Related]
8. Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
Määttä KM; Nurminen R; Kankuri-Tammilehto M; Kallioniemi A; Laasanen SL; Schleutker J
BMC Cancer; 2017 Jul; 17(1):496. PubMed ID: 28738860
[TBL] [Abstract][Full Text] [Related]
9. Human DNA helicase HELQ participates in DNA interstrand crosslink tolerance with ATR and RAD51 paralogs.
Takata K; Reh S; Tomida J; Person MD; Wood RD
Nat Commun; 2013; 4():2338. PubMed ID: 24005565
[TBL] [Abstract][Full Text] [Related]
10. HELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesis.
Adelman CA; Lolo RL; Birkbak NJ; Murina O; Matsuzaki K; Horejsi Z; Parmar K; Borel V; Skehel JM; Stamp G; D'Andrea A; Sartori AA; Swanton C; Boulton SJ
Nature; 2013 Oct; 502(7471):381-4. PubMed ID: 24005329
[TBL] [Abstract][Full Text] [Related]
11. Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication.
Pelttari LM; Shimelis H; Toiminen H; Kvist A; Törngren T; Borg Å; Blomqvist C; Bützow R; Couch F; Aittomäki K; Nevanlinna H
Clin Genet; 2018 Mar; 93(3):595-602. PubMed ID: 28802053
[TBL] [Abstract][Full Text] [Related]
12. Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer.
Jønson L; Ahlborn LB; Steffensen AY; Djursby M; Ejlertsen B; Timshel S; Nielsen FC; Gerdes AM; Hansen TV
Breast Cancer Res Treat; 2016 Jan; 155(2):215-22. PubMed ID: 26740214
[TBL] [Abstract][Full Text] [Related]
13. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
Long J; Zhu JY; Liu YB; Fu K; Tian Y; Li PY; Yang WQ; Yang SY; Yin JY; Yin G; Zhang Y
Gynecol Oncol; 2018 May; 149(2):341-349. PubMed ID: 29572031
[TBL] [Abstract][Full Text] [Related]
14. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
Hartikainen JM; Kataja V; Pirskanen M; Arffman A; Ristonmaa U; Vahteristo P; Ryynänen M; Heinonen S; Kosma VM; Mannermaa A
Clin Genet; 2007 Oct; 72(4):311-20. PubMed ID: 17850627
[TBL] [Abstract][Full Text] [Related]
15. Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.
Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
Breast Cancer Res Treat; 2014 Jun; 145(3):775-84. PubMed ID: 24800917
[TBL] [Abstract][Full Text] [Related]
16. Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families.
Johnson J; Healey S; Khanna KK; ; Chenevix-Trench G
Breast Cancer Res Treat; 2011 Aug; 129(1):255-63. PubMed ID: 21533530
[TBL] [Abstract][Full Text] [Related]
17. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
[TBL] [Abstract][Full Text] [Related]
18. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
[TBL] [Abstract][Full Text] [Related]
19. RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families.
Krivokuca A; Yanowski K; Rakobradovic J; Benitez J; Brankovic-Magic M
Cancer Biomark; 2015; 15(6):775-81. PubMed ID: 26406419
[TBL] [Abstract][Full Text] [Related]
20. RAD51C is a susceptibility gene for ovarian cancer.
Pelttari LM; Heikkinen T; Thompson D; Kallioniemi A; Schleutker J; Holli K; Blomqvist C; Aittomäki K; Bützow R; Nevanlinna H
Hum Mol Genet; 2011 Aug; 20(16):3278-88. PubMed ID: 21616938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
